Covered recipient · General Payments record
BRYNNE K NOSKO
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant
General Payments · PY2021
$272.42
- Reported across 16 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2021 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $272.42 | 16 |
By paying entity
PY2021 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $134.82 | 8 |
| Amarin Pharma Inc. | $34.72 | 2 |
| Nabriva Therapeutics, plc | $22.60 | 1 |
| Abbott Laboratories | $20.38 | 1 |
| ARBOR PHARMACEUTICALS, INC. | $16.56 | 1 |
| Biohaven Pharmaceuticals, Inc. | $16.20 | 1 |
| PFIZER INC. | $14.57 | 1 |
| Kowa Pharmaceuticals America, Inc. | $12.57 | 1 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2021 | $272.42 | 16 |
Payment records · PY2021 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $20.38 | 08/06/2021 | Food and Beverage | Undisputed | 01/23/2026 | 833819245 | CMS |
| AbbVie Inc. | $17.75 | 03/03/2021 | Food and Beverage | Undisputed | 01/23/2026 | 795061263 | CMS |
| AbbVie Inc. | $16.20 | 03/19/2021 | Food and Beverage | Undisputed | 01/23/2026 | 795061267 | CMS |
| AbbVie Inc. | $16.95 | 05/21/2021 | Food and Beverage | Undisputed | 01/23/2026 | 795061271 | CMS |
| AbbVie Inc. | $29.98 | 06/02/2021 | Food and Beverage | Undisputed | 01/23/2026 | 795061275 | CMS |
| AbbVie Inc. | $7.40 | 06/07/2021 | Food and Beverage | Undisputed | 01/23/2026 | 795061279 | CMS |
| AbbVie Inc. | $11.99 | 06/21/2021 | Food and Beverage | Undisputed | 01/23/2026 | 795061283 | CMS |
| AbbVie Inc. | $18.26 | 07/23/2021 | Food and Beverage | Undisputed | 01/23/2026 | 795061287 | CMS |
| AbbVie Inc. | $16.29 | 08/23/2021 | Food and Beverage | Undisputed | 01/23/2026 | 795061291 | CMS |
| Amarin Pharma Inc. | $15.67 | 07/14/2021 | Food and Beverage | Undisputed | 01/23/2026 | 815255379 | CMS |
| Amarin Pharma Inc. | $19.05 | 08/07/2021 | Food and Beverage | Undisputed | 01/23/2026 | 815255381 | CMS |
| ARBOR PHARMACEUTICALS, INC. | $16.56 | 04/16/2021 | Food and Beverage | Undisputed | 01/23/2026 | 830940591 | CMS |
| Biohaven Pharmaceuticals, Inc. | $16.20 | 08/17/2021 | Food and Beverage | Undisputed | 01/23/2026 | 852782773 | CMS |
| Kowa Pharmaceuticals America, Inc. | $12.57 | 04/06/2021 | Food and Beverage | Undisputed | 01/23/2026 | 805543863 | CMS |
| Nabriva Therapeutics, plc | $22.60 | 04/27/2021 | Food and Beverage | Undisputed | 01/23/2026 | 844878367 | CMS |
| PFIZER INC. | $14.57 | 06/14/2021 | Food and Beverage | Undisputed | 01/23/2026 | 833520429 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021
- Source files
- Dataset page · Bulk file · PY2021
- Generated from
- OP_DTL_GNRL_PGYR2021_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.